Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept
FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.
FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.